Sera Prognostics Inc (NASDAQ:SERA) — Market Cap & Net Worth
Market Cap & Net Worth: Sera Prognostics Inc (SERA)
Sera Prognostics Inc (NASDAQ:SERA) has a market capitalization of $71.04 Million ($71.04 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20637 globally and #4609 in its home market, demonstrating a -11.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sera Prognostics Inc's stock price $1.86 by its total outstanding shares 38190966 (38.19 Million). Review total liabilities of Sera Prognostics Inc to assess the company's total debt and financial obligations.
Sera Prognostics Inc Market Cap History: 2021 to 2026
Sera Prognostics Inc's market capitalization history from 2021 to 2026. Data shows change from $262.37 Million to $71.04 Million (-31.41% CAGR).
Index Memberships
Sera Prognostics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #588 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1989 of 3165 |
Weight: Sera Prognostics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sera Prognostics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sera Prognostics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1390.91x
Sera Prognostics Inc's market cap is 1390.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $262.37 Million | $82.00K | -$35.01 Million | 3199.66x | N/A |
| 2022 | $48.12 Million | $268.00K | -$44.19 Million | 179.55x | N/A |
| 2023 | $228.38 Million | $306.00K | -$36.24 Million | 746.35x | N/A |
| 2024 | $310.87 Million | $77.00K | -$32.90 Million | 4037.33x | N/A |
| 2025 | $112.66 Million | $81.00K | -$31.93 Million | 1390.91x | N/A |
Competitor Companies of SERA by Market Capitalization
Companies near Sera Prognostics Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Sera Prognostics Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #149 globally with a market cap of $157.58 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #205 globally with a market cap of $118.86 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #236 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #244 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #149 | Abbott Laboratories | NYSE:ABT | $157.58 Billion | $90.62 |
| #205 | Stryker Corporation | NYSE:SYK | $118.86 Billion | $310.58 |
| #236 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #244 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $81.32 |
Sera Prognostics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Sera Prognostics Inc's market cap moved from $262.37 Million to $ 71.04 Million, with a yearly change of -31.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $71.04 Million | -36.95% |
| 2025 | $112.66 Million | -63.76% |
| 2024 | $310.87 Million | +36.12% |
| 2023 | $228.38 Million | +374.60% |
| 2022 | $48.12 Million | -81.66% |
| 2021 | $262.37 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Sera Prognostics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $71.04 Million USD |
| MoneyControl | $71.04 Million USD |
| MarketWatch | $71.04 Million USD |
| marketcap.company | $71.04 Million USD |
| Reuters | $71.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of… Read more